Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

424B5 - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

CHARLOTTE, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced its participation in the following upcoming investor conferences. The Company will participate in The Benchmark Company's 14th Annual Discovery One-on-One Conference, taking place December 4, 2025, at the New York Athletic Club in New York City. Prenetics Chief Executive Officer Danny Yeung will be available for one-on-one meetings with investors during the conference. The Company will also participate in Sidoti's Year End Virtual Investor Conference, being held

CHARLOTTE, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8 and a global health-tech and longevity company pioneering a dual-engine strategy across consumer wellness and Bitcoin, today announced that all key members of its executive leadership team have executed open market purchases of Prenetics' common stock during the Company's designated trading window. In total, the executive team acquired 111,911 shares of Prenetics' common stock for an aggregate purchase price of approximately $1,446,887. Individual Transaction Details Danny Yeung, Chief Executive OfficerIn two open market transactions on Novem

IM8's Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial Position Cantor Forecasts $217 Million in FY2026 Revenue as IM8 Expands Internationally and Sharpens Strategic Focus CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that Cantor Fitzgerald has reiterated its Overweight rating on the Company in its latest equity research report dated November 11, 2025, while updating i

Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September 30, 2025 before market open on Monday, November 10, 2025. The Company will also hold its first ever earnings conference call the same day at 8:30 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Monday, November 10, 2025Time:8:30 a.m. Eastern TimeDial-in:1-844-425-9470International Dial-in:201-298-0878WebcastPRE Conference Call An audio replay of the webcast will

~ October Revenue Grew 32% MoM and on Track to hit $10 Million in Monthly Revenue by December 2025 ~ CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced a record breaking month for IM8 in October, reaching approximately $108 million in annualized recurring revenue (ARR) just 11 months after its commercial launch. Building on the momentum from last week's successful $44 million equity offering, IM8 is positioned for accelerated global expansion and enhanced partnerships. Key highlights: IM8 delivered its strongest month to date in

Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering Company now holds a total of 378 BTC (valued at ~$46 Million) CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announces the acquisition of 100 Bitcoin, at an average price of $109,594 per Bitcoin. This acquisition demonstrates the Company's dedication and continued discipline to building its Bitcoin treasury. Strategic Capital Deployment Following Successful Equity Raise This Bitcoin acquisition represents the initial deployment of proceeds from Prenetics' recently completed $44 million equity

Comprehensive Document Reveals Strategic Vision Behind Company's Unprecedented Growth and Bitcoin Treasury Strategy IM8, the Fastest-Growing Supplement Brand in Industry History, Reaching Reaches $100M ARR in 11 Months Since Launch IM Projects $180-$200 Million in FY 2026 Revenue CHARLOTTE, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE ("Prenetics" or the "Company"), a leading health sciences company, today announced the publication of a comprehensive manifesto authored by CEO and Co-Founder Danny Yeung, titled "The Dual-Engine Revolution: A Manifesto for Building the Future of Health + Wealth." The document provides unprecedented transparency into the Fo

CHARLOTTE, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced the closing of its previously announced best efforts public offering (the "Offering") of (i) 2,722,642 Class A ordinary shares, par value $0.0015 per share, of the Company (the "Ordinary Shares," the Ordinary Shares being sold in the Offering, the "Shares"), (ii) warrants of the Company to purchase up to 2,722,642 Ordinary Shares (the "Class A Common Warrants"), and (iii) warrants of the Company to purchase up to 2,722,642 Ordinary Shares (the "Class B Common Warrants" and together with the Class A Common Warrants, the "

Distinguished Investor Group Includes Kraken, American Ventures, Exodus (NYSE:EXOD), XtalPi (2228.hk), DL Holdings (1709.hk) GPTX by Jihan Wu and Leading Institutions World No. 1 and 4-time Grand Slam champion Aryna Sabalenka expands her stake in Prenetics Adrian Cheng, one of Asia's most influential visionaries and an original cornerstone investor in Prenetics' IPO increases his stake, reflecting enduring conviction in the company's global vision IM8 Achieves $100 Million in Annual Recurring Revenue Within 11 Months of Launch IM8 Guidance $180 to $200 Million Revenue in 2026, Driving Company Toward Multi-Billion Dollar Valuation Prenetics CEO Danny Yeung to Host Investor Conference Cal

-  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation -  Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an averag

LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September 30, 2025 before market open on Monday, November 10, 2025. The Company will also hold its first ever earnings conference call the same day at 8:30 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Monday, November 10, 2025Time:8:30 a.m. Eastern TimeDial-in:1-844-425-9470International Dial-in:201-298-0878WebcastPRE Conference Call An audio replay of the webcast will

Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering Company now holds a total of 378 BTC (valued at ~$46 Million) CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announces the acquisition of 100 Bitcoin, at an average price of $109,594 per Bitcoin. This acquisition demonstrates the Company's dedication and continued discipline to building its Bitcoin treasury. Strategic Capital Deployment Following Successful Equity Raise This Bitcoin acquisition represents the initial deployment of proceeds from Prenetics' recently completed $44 million equity

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Prenetics management to develop and implement a capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight how Prenetics is at the forefront of cutting-edge technological advancements in health and wellness. Under the Prenetics umbre

(Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government. - By 2030, the early cancer detection screening opportunity is estimated to be US$6bn in Asia on an annual basis.1 - Prof. Dennis Lo is the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong (CUHK) and the Scientific Director of the Centre for Novostics. HONG KONG, June 25, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leadi

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and moreExpects ACT to contribute US$25-30 million in revenues in 2023Positions Prenetics solidly within the US$80+ billion global precision oncology marketAcquisition expected to complete on or around December 30, 2022, subject to normal closing conditions LONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PR

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $9.47875000 per share on the company’s 5.250% fixed-to-floating rate non-cumulative preferred stock, Series C, with a liquidation preference of $1,000 per share. Semi-annual dividend of $29.375 per share on the company’s 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company’s 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13D - Prenetics Global Ltd (0001876431) (Subject)

SC 13D/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13D/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13D - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G - Prenetics Global Ltd (0001876431) (Subject)